Across TCGA pan-cancer cohorts, LINC02692 RNA differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of LINC02692’s most consistent transcriptional readouts.

The strongest signal is observed in prostate adenocarcinoma (PRAD), where LINC02692 RNA is repressed in tumor relative to normal tissue. In most cancer types LINC02692 is over-expressed in tumor, although a few such as PRAD and LUSC show the opposite, repressed pattern.

PRAD, LUSC, and STAD are the cancer types where LINC02692 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in LINC02692 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
PRAD	All	All	−0.374	.004	2	view →
LUSC	Female	All	−0.060	.003	1	view →
STAD	Male	II,III,IV	+0.044	.043	1	view →
THCA	All	II,III,IV	−0.030	.019	1	view →
KICH	All	All	−0.028	.035	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: LINC02692 RNA expression & survival · all LINC02692 data types